Marilyn Metcalf is the Director of Benefit Risk Evaluation at GlaxoSmithKline. Her team leads GSK’s efforts to measure and monitor the favorable v. unfavorable effects of medicines and vaccines. She has worked in nonprofit and industry health related research, beginning her current role in 2011.
Marilyn Metcalf is the Director of Benefit Risk Evaluation at GlaxoSmithKline. Her team leads GSK’s efforts to measure and monitor the favorable v. unfavorable effects of medicines and vaccines. She has worked in nonprofit and industry health related research, beginning her current role in 2011.
Visiting Professor of Decision Science at the London School of Economics. Awarded the Frank P. Ramsey medal for "distinguished contributions to decision analysis" by the Decision Analysis Society of INFORMS.
Description
This session will provide a discussion of the continuum of benefit-risk assessment models, ranging from personal mental models to more formal qualitative and quantitative models.
Learning Objectives: Demonstrate an appreciation of mental models and the value of making them explicit Discuss how benefit-risk framing places implicit requirements on data and communication Describe new graphical approaches for benefit-risk communication.